Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Video Expert Opinion
Colleague Insights
Conferences
Sign in
Join now
story of the week
Published in Multiple Sclerosis

Journal Scan / Research · October 14, 2024

Association Between sNfL Levels and 12-Month Outcomes in Patients With MS

Journal of Neurology

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Ahmed Obeidat MD, PhD

Journal of Neurology
In multiple sclerosis patients a single serum neurofilament light chain (sNFL) dosage is strongly associated with 12 months outcome: data from a real-life clinical setting
J Neurol 2024 Sep 23;[EPub Ahead of Print], S Malucchi, CI Bava, P Valentino, S Martire, M Lo Re, A Bertolotto, A Di Sapio

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated